The first Arterium products registered in Australia
Two Arterium products were registered in Australia in April: Magnesium sulfate 50% (solution for injection) and Moxifloxacin (solution for infusion). Both medicines will participate in the tender procurement.
In particular, Magnesium sulfate 50% is used in Australia in inpatient practice for the treatment of obstetric complications (eclampsia), hypomagnesemia and a number of other conditions that threaten the lives of women during childbirth.
In 2020, Magnesium sulfate 50% by Arterium became the first domestic drug to be prequalified by the WHO. This is a procedure for confirming the high level of quality, safety and efficacy of medicines by the WHO.